New Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products of 2014

Print 10 December 2014
U.S. Food and Drug Administration

Innovation drives progress. When it comes to innovation in the development of new drugs and therapeutic biological products, FDA’s Center for Drug Evaluation and Research (CDER) supports the pharmaceutical industry at every step of the process. With its understanding of the science used to create new products, testing and manufacturing procedures, and the diseases and conditions that new products are designed to treat, FDA provides scientific and regulatory advice needed to bring new therapies to market.

The availability of new drugs and biological products often means new treatment options for patients and advances in health care for the American public. For this reason, CDER supports innovation and plays a key role in helping to advance new drug development. 

Each year, CDER approves a wide range of new drugs and biological products. Some of these products are innovative new products that never before have been used in clinical practice. Others are the same as, or related to, previously approved products, and they will compete with those products in the marketplace.

Certain drugs are classified as new molecular entities (“NMEs”) for purposes of FDA review. Many of these products contain active moieties that have not been approved by FDA previously, either as a single ingredient drug or as part of a combination product; these products frequently provide important new therapies for patients. Some drugs are characterized as NMEs for administrative purposes, but nonetheless contain active moieties that are closely related to active moieties in products that have previously been approved by FDA. For example, CDER classifies biological products submitted in an application under section 351(a) of the Public Health Service Act as NMEs for purposes of FDA review, regardless of whether the Agency previously has approved a related active moiety in a different product. FDA’s classification of a drug as an “NME” for review purposes is distinct from FDA’s determination of whether a drug product is a “new chemical entity” or “NCE” within the meaning of the Federal Food, Drug, and Cosmetic Act.

The list includes the NMEs and BLAs approved by CDER in calendar year 2014 here.

Source

* - The 2013 filed numbers include those filed in CY 2013 plus those currently pending filing (i.e., within their 60 day filing period) in CY 2013. 
   - Receipts that received a “Refuse to File” (RTF) or “Withdrawn before filing” (WF) identifier are excluded. 
   - Multiple submissions (multiple or split originals) pertaining to a single new molecular/biologic entity are only counted once. 
   - There is a BLA included that does not currently have a review schedule but is known to contain a new active ingredient. 
   - The filed number is not indicative of workload in the PDUFA V Program.

More charts pulled from the 2013 Novel New Drug Summary Report - here. 

Return